

Product Name : Toceranib

**Synonyms** : SU11654,PHA 291639E

Cat No. : M22125

**CAS Number** : 356068-94-5

Molecular Formula : C22H25FN4O2

Formula Weight : 396.46

Chemical Name : ----

Toceranib phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR,

and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively), has antitumor and antiangiogenic

**Description** : activity. Administration of toceranib significantly decreased the number and percentage of Treg in the peripheral blood of

dogs with cancer. Dogs receiving toceranib and CYC demonstrated a significant increase in serum concentrations of IFN-y,

which was inversely correlated with Treg numbers after 6 weeks of combination treatment.

Pathway : Angiogenesis

Target : PDGFR

Receptor : PDGFR;VEGFR;Kit

**Solubility** : DMSO:2.4 mg/mL (6.05 mM; Need ultrasonic)

**SMILES** : Cc1[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c(C)c1C(=O)NCCN1CCCC1

Storage : (-20°C)

Stability : ≥ 2 years

Reference :

1. Mitchell L, et al. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med. 2012 Mar-Apr; 26(2):355-62.